Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial

医学 疾病 内科学 临床试验 相(物质) 梅德林 重症监护医学 临床研究阶段 外科 不利影响
作者
Ghaith Noaiseh,Kathy L. Sivils,Kim Campbell,Jada Idokogi,Kim Hung Lo,Sophia G. Liva,Jocelyn H. Leu,Harman Dhatt,Keying Ma,Steven Leonardo,Li He,Jonathan J. Hubbard,Jacques-Éric Gottenberg
出处
期刊:The Lancet [Elsevier BV]
卷期号:406 (10518): 2435-2448 被引量:14
标识
DOI:10.1016/s0140-6736(25)01430-8
摘要

BACKGROUND: Sjögren's disease is characterised by mucosal dryness, fatigue, chronic pain, systemic organ involvement, and elevated autoreactive IgG antibodies. There are no approved disease-modifying treatments. Therefore, we aimed to evaluate nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG, including autoantibodies, in patients with Sjögren's disease. METHODS: This phase 2, double-blind, multicentre trial enrolled individuals with moderate-to-severe, active Sjögren's disease (ie, Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index [ClinESSDAI] of at least 6) who were seropositive for anti-Ro IgG autoantibodies. Participants were recruited from 69 centres across France, Germany, Italy, Japan, the Netherlands, Poland, Portugal, Spain, Taiwan, and the USA. These centres included rheumatology centres, hospitals, and clinical research centres with experience conducting pharmaceutical company-sponsored phase 2 and phase 3 studies, which reported an ability to enrol eligible patients. Central randomisation assigned participants to one of three treatment groups using an Interactive Web Response System. Randomised (1:1:1) participants received intravenous nipocalimab 5 mg/kg, intravenous nipocalimab 15 mg/kg, or placebo every 2 weeks for 22 weeks. Schedules for administering the study intervention were the same across treatment groups, and labels on the study interventions were prepared by an unmasked pharmacist and were identical to maintain masking for the participants, investigators, site staff, and sponsor. The primary endpoint was change from baseline in ClinESSDAI score at week 24. The primary endpoint and other efficacy and safety analyses included participants who were randomly assigned and who received at least one dose of study intervention. For the primary endpoint, data from the time of discontinuation and onward were considered missing. The primary analysis approach used a mixed model for repeated measures to estimate the average outcome, taking into account the non-missing data and variability. DAHLIAS was registered with EudraCT (2021-000665-32) and ClinicalTrials.gov (NCT04968912) and has been completed. FINDINGS: 163 participants were recruited between Sept 21, 2021, and April 3, 2023, (53 participants to nipocalimab 5 mg/kg, 54 to nipocalimab 15 mg/kg, and 56 to the placebo). The mean age of participants was 48·1 years (SD 12·12); 151 (93%) participants were female and 12 (7%) were male. The nipocalimab 15 mg/kg group had a significant reduction in ClinESSDAI score at week 24 versus the placebo group (least squares mean difference -2·65, 90% CI -4·03 to -1·28; p=0·0018), and the nipocalimab 5 mg/kg group had a non-significant reduction versus placebo (-0·34, -1·71 to 1·03; p=0·68). The safety profile of nipocalimab was comparable, for both doses, with that of placebo, with generally similar rates of adverse events and serious adverse events across groups. INTERPRETATION: Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's disease. Reductions in IgG autoantibodies during nipocalimab treatment support their contribution to Sjögren's disease pathogenesis. FUNDING: Johnson & Johnson.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
初初初啊发布了新的文献求助10
刚刚
fanxiare发布了新的文献求助10
1秒前
今后的应助被是小周采纳,获得10
1秒前
renn发布了新的文献求助30
1秒前
水天需发布了新的文献求助10
2秒前
2秒前
华仔的应助被别急采纳,获得10
2秒前
英俊的铭的应助被正直的夏青采纳,获得30
3秒前
3秒前
王彬完成签到,获得积分10
4秒前
4秒前
小二郎的应助被廖喜林采纳,获得10
4秒前
XU发布了新的文献求助10
4秒前
天天快乐的应助被fei采纳,获得10
5秒前
6秒前
gispy完成签到,获得积分10
8秒前
gyz发布了新的文献求助10
8秒前
ijjh完成签到,获得积分10
8秒前
8秒前
Lesia发布了新的文献求助20
8秒前
科研通AI2S的应助被lp采纳,获得10
8秒前
mjw发布了新的文献求助10
8秒前
王彬发布了新的文献求助10
9秒前
Ava的应助被然然采纳,获得30
9秒前
9秒前
Lee完成签到,获得积分10
9秒前
10秒前
JiaYouguo完成签到,获得积分10
10秒前
Anonymous的应助被可可采纳,获得20
10秒前
fanxiare完成签到,获得积分10
11秒前
FashionBoy的应助被小豆糕采纳,获得10
11秒前
renn发布了新的文献求助10
11秒前
胡图图不糊涂完成签到,获得积分10
11秒前
郭姗姗发布了新的文献求助10
12秒前
Superman完成签到,获得积分10
13秒前
热情访风发布了新的文献求助10
13秒前
浮云发布了新的文献求助20
14秒前
14秒前
zi完成签到,获得积分20
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183923
求助须知:如何正确求助?哪些是违规求助? 9573132
关于积分的说明 21829461
捐赠科研通 7781024
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558333
邀请新用户注册赠送积分活动 2480648